People

LEVY Health is the first Clinical Decision Support Software (CDSS) that enables healthcare providers to expand their scope of practice to treat more patients. Aligned with clinical guidelines, our software serves as a valuable ally for clinical staff and OB-GYNs. It takes charge of pre-screening, lab ordering and analysis, triaging, and result interpretation. By automizing those responsibilities, our software offers tailored diagnostic insights and treatment recommendations, ensuring a more efficient and comprehensive approach to patient care. This broadens access to reproductive care by empowering providers to build more families.

RevoNA holds huge potential in treating currently ‘undruggable’ diseases by overcoming the challenges associated with targeting RNA. Conventional approaches are slow and costly, limited by inadequate R&D tools and RNA complexity, resulting in a shortage of crucial data in the field. Next-generation technologies are essential to unlocking the necessary data to drive RNA Drug discovery forward. RevoNA’s innovative solution integrates a novel high-throughput RNA biological platform, that rapidly amasses premium RNA datasets enriched with diverse information. These comprehensive datasets feed a complementary AI prediction engine build, that will enable RevoNA to significantly reduce the time-to-market for RNA-targeted drugs and make discovery affordable at scale.

Tetratherix has developed a proprietary, fully synthetic biomaterial that is compatible with minimally invasive administration techniques and does not induce any foreign body reaction, a genuine biostealth platform technology. The company has active development programs in the areas of regenerative medicine and mRNA delivery. Our world-leading team has spent a decade, inventing and developing the biomaterial technology and has proven its safety and efficacy as the world’s first biostealth matrix.

Zafrens exists to bring the life sciences to the AI era using cutting edge engineering tools. The costs and pace of data generation in biology/chemistry lag behind our ability to process data by many, many orders of magnitude. Zafrens aim to bridge this gap by developing ultra-high throughput, ultra-high resolution approaches to studying cells, both at the single-cell level and in the context of cell-cell interactions in various co-cultures. Considering the quickest way to understand complex systems is to perturb them, and thus the team have built a versatile platform that allows us to probe profound, complex questions by simply swapping the inputs to the system.

The future of mRNA technology is hampered by manufacturing challenges and unless solved, its exciting potential may never be realised. Sensible Biotechnologies is on a journey to solve this problem by turning living cells into factories producing abundant, highly stable and non-immunogenic mRNA on demand.

Opto Bio is developing miniaturised implants that are safe, effective, and minimally invasive. Opto believes that that the application of discreet, safe biological interfaces will enable remote and continuous neurological communication, changing the way we approach medicine by using the electrical language of the body. Advancing the frontiers of biological interfacing, Opto is using new electrical biomarkers that can be used to inform disease state in real time. Opto aims to improve patient outcomes and revolutionise precision treatment through their research, development, and clinical testing.

At Enveda, they are systematically translating molecules found in medicinal plants into new drugs for challenging diseases. This platform harnesses nature's complexity with the help of cutting-edge advancements in knowledge graphs, machine learning, and metabolomics. Enveda is starting a movement to create the next generation of small molecule therapeutics.

Chemify's technology enables the full stack digitization of chemistry from code to molecules and molecules to code for molecular discovery, optimization, and synthesis. They make the chemical synthesis of complex new molecules significantly faster, perfectly reproducible, and create large functional libraries of unprecedented scale.

With a strong foundation of fundamental research, Inventia has developed a proprietary platform encompassing drop-on-demand bio-printing technology, an expanding library of printable matrices and custom protocols for specific applications. The RASTRUM platform is now available to enable efficient and powerful bio-printing of 3D cell-based assays for biomedical research.

Climate change is driving a transformative pivot in agriculture towards high-tech soilless greenhouses. These drastically reduce water use and emissions while significantly increasing yields. However, like humans need our gut microbiome, plants rely on the soil microbiome. This is missing in soilless agriculture, leading to reduced plant health and yield. Concert Bio addresses this by giving growers all the tools they need to create and manage an optimal microbiome in their system. Their proprietary platform gives growers unprecedented insights into their existing microbiome and uses that date to identify novel plant-beneficial microbes.

Automata aims to enable new opportunities for innovation through total workflow automation accessible to labs frustrated by the limitations of their own environment. Automata works with labs across the world to understand their specific workflows and needs, and develop personalised solutions that range from diagnostic, drug discovery to synthetic biology. This allows a simplification of common automation tasks, while also supporting more advanced paths for specialised workflows, in a fast, flexible, and cost-efficient way.

Hello Inside provides the user with intelligent, personalised insights based on their food intake and glycemic response (the effect that food or meal has on blood sugar levels after consumption - something that differs for each of us). The Continuous Glucose Monitoring patch has a small, sub-cutaneous needle which detects the glucose levels in blood and transmits the readings via bluetooth to any connected device. Hello Inside will leverage this technology to build a personalised health platform for consumers.

Food businesses leverage Cookaborough's end-to-end platform to build their menu on a branded webpage, take and aggregate orders in advance, manage ingredients, create labels and organise delivery.

Exakt Health's mobile app leads users through "self-diagnosis" for standard sports injuries and offers customised professional physiotherapy plans for different conditions. Exakt will first focus on running-related injuries, prior to expanding to other rehabilitation segments. The app provides free and easy access to sports physiotherapists and doctors' expertise through modern technology. No commute. No waiting rooms.

Mass Dynamics' cloud-based software is designed from the bottom up for all the stakeholders in the project workflow: biologists, chemists, mass spec. experts and scientific report writers. There are two core features behind this initial version: a 'compute' module to run the massive data processing workflow, and a 'sharing and collaboration' module for teams to share insights and communicate.

There are two parts to the Flow Bio system, a sensor made up of electrodes and micro-fluidics channels (this part is disposable), and a shell that holds the battery, electronics, RAM etc. Data is then displayed on a connected app where FlowBio's own data will be displayed and can be connected to other 3rd party data. The first biomarkers will be potassium, sodium and sweat rate to provide the most comprehensive and real-time view into hydration status.

Heidi is building the gateway for patients anywhere in the world to get the care they need rapidly, easily and cheaply while providing every doctor with the tools to provide modern care that is safe, productive and deeply satisfying.

Edgeless Systems is building an open-source framework to enable secure communications for the next generation of confidential computing. Confidential computing is a cloud computing technology that isolates sensitive data in encrypted and verifiable CPU enclaves (i.e. hardware) during processing. The contents of the enclave, including the data being processed and the techniques used to process it, are accessible only to authorised programming code, remaining invisible to anything or anyone else, including cloud providers.

Avi Medical plans to operate modern and efficient medical centers to optimise and control the process of primary care, end-to-end. The medical centers are utilising state-of-the art digital infrastructure with an app for patients and a modern software stack for doctors. This brings process efficiency, a welcoming user experience before, during and after GP visits, 24/7 access to medical support and accurate diagnosis and treatments to the patients.

Molecule is a digital interface matching supply and demand for biotech and pharma assets. Most of those assets currently live inside universities, small biotech companies, and, increasingly, AI drug discovery companies. Molecule crawls and lists research projects and enriches the data over time (this is increasingly done by researchers themselves who "claim" and develop their profiles). Interested investors can search pre-vetted projects depending on their therapeutic area, clinical stage and type of project.

prePO gives people the opportunity to trade synthetic assets as a proxy for investing in private markets. Why speculation? Asset ownership is a scarcity play by default due to the limited number of shares or tokens on offer, which then limits the number of people that can access the opportunity. By allowing speculation on an opportunity, prePO enables an unlimited number of participants in the upside or downside of the opportunity.

Blockchain technology creates new opportunities for game developers to incentivise players with real-world gain, offering a powerful dynamic in the race to attract and retain players. As this technology emerges, players will expect the ability to create real world value whilst playing games. Immutable's making it easy for game developers to enable that.

In an era where personal information is no longer private and passwords are commonly reused, stolen or cracked, the traditional method of protecting access to data and services by username and password has repeatedly proven to be inadequate. Keyless is a team of scientists and entrepreneurs pioneering a solution to this large-scale structural issue of the internet. The Keyless team have built a novel biometric authentication platform that eliminates the need for businesses to store and manage passwords, biometric data, cryptographic keys and other sensitive personal information, without compromising on convenience and privacy for their employees or end-users. We’re pumped to watch the Keyless team build the future of authentication.

Today's teachers are shifting a lot of their classes online, especially following a period marked by continual lockdowns and school closures across the world. However existing online solutions do not meet the requirements for creating effective educational environments. Koala is an ed-tech company building a horizontal platform to enable teachers to create their own virtual classrooms. We think of Koala as a "no code" tool for teachers to create their online learning environments and content. We’re stoked to back the Koala team as they build the future of online classrooms.

At the heart of the drug discovery and development process lies an indisputable truth: companies can test for many compounds but, in order to advance to further stages, they need to be able to manufacture it. Molecule.One is an AI-driven chemist that predicts the best possible synthetic pathways for any desired compound. Their software platform, powered by state-of-the-art machine learning models, discovers the cheapest and easiest way to synthesize any given compound from commercially available molecules. We’re excited to support the team as they build the future of chemistry.

Imagine a world where drugs are tested not on animals but on actual human cells before they reach clinical trials. Imagine that every patient could receive therapeutics that are proven to be effective on that particular patient, not just the general population. This could save years of trial and error and patient suffering. We’re thrilled to back SUN Biosciences, who are building the foundations for this future by standardising organoid culture to build a single source of biological truth for drug testing, development and application. Their unique technology solves some of the core issues that have been holding organoids back.

Every industry that is doing complex computation, simulation and optimization is bound by limited computing power. Quantum is computing’s next step. Quantum’s potential for impact is tremendous and we’re excited to support the Seeqc team as they build the future of quantum computing. Seeqc develops and commercializes superconducting quantum technologies for a variety of quantum information processing applications including scalable fault-tolerant quantum computers and simulators, quantum communications, and quantum sensors.

Trading cards have been popular long before digital worlds were even imagined. Until recently, challenges around authenticating digital items made it nearly impossible to create scarcity (and therefore value) for digital trading cards. Today crypto, (and the underlying blockchain technology) makes authenticating digital trading cards possible. Sorare uses blockchain technology to build a digital fantasy football league, where users collect, trade and compete with their favourite player's cards (NFTs). Users play fantasy football with these player cards and earn real world rewards based on the performance of their players in real world competitions.

Mental disorders account for one of the largest and fastest growing categories of the burden of disease worldwide. Mental ill-health has devastating effect on individuals, families and communities, and weighs heavily on societies and economies - the economic burden of mental ill-health can rise to up to 4% of GDP, and those with mental illness have poorer educational and work outcomes than those in good mental health. Psylo is building a proprietary platform for developing psychedelic medicines to redefine how we treat mental illness. The Psylo team is uniquely positioned to transform mental health treatment with the application of psychedelics. Collectively, they bring years of experience researching cannabinoids and building deep biotech companies. And, like all great company-builders, the founding team has assembled a supporting tribe of industry-leading biotech investors and psychedelic experts.